Stay updated on Cabozantinib in Salivary Gland Cancer: Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Salivary Gland Cancer: Clinical Trial page.
Latest updates to the Cabozantinib in Salivary Gland Cancer: Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no new study information, endpoints, eligibility criteria, or contacts were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a dedicated Locations section with Gelderland as a location. Removed the old Gelderland Locations label and the HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check53 days agoChange DetectedMinor wording changes related to the PubMed publications note and versioning were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check60 days agoChange DetectedRemoved the government funding status notice as an administrative update; no impact on study details, eligibility criteria, outcomes, or scheduling. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check67 days agoChange DetectedNo additions or deletions were detected; the study details page remains unchanged.SummaryDifference0.5%
- Check103 days agoChange DetectedMajor content and status update: add Adenoid cystic carcinoma and government-operating notice, update to v3.2.0; remove Adrenal cortex carcinoma and v3.1.0.SummaryDifference3%
Stay in the know with updates to Cabozantinib in Salivary Gland Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Salivary Gland Cancer: Clinical Trial page.